Literature DB >> 27757787

Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants.

Molly Howard1, Andrew Lipshutz2, Breanne Roess3, Emily Hawes4, Zachariah Deyo5, Jena Ivey Burkhart5, Stephan Moll6, Betsy Bryant Shilliday7.   

Abstract

Direct Oral Anticoagulants (DOACs) require specific dosing and monitoring to ensure safe and appropriate use. The purpose of this evaluation was to identify patient- and process-related factors that correlate with increased risk of inappropriate prescribing of DOACs. A retrospective chart review was conducted in three outpatient clinics within an academic medical center to identify patients started on DOAC therapy and evaluate the appropriateness of DOAC initiation. Data collected included patient demographics, DOAC medication initiated, dose, indication, baseline laboratory values, concomitant medications, type and specialty of prescriber, and initiation setting. Appropriateness of initial dose was assessed and data were analyzed in order to identify factors correlating with inappropriate use. One-hundred sixty-seven patients initiated on a DOAC were identified. Most patients were prescribed anticoagulation for atrial fibrillation (74.9 %) and most commonly prescribed rivaroxaban (62.9 %). An inappropriate dose was prescribed in 24 (14.4 %) patients. Female patients and patients over 75 years were more likely to be prescribed an inappropriate initial dose. Baseline evaluation of blood counts and organ function were often not performed: hemoglobin values had not been drawn within the month prior to initiation in 28.7 % of patients, serum creatinine in 22.8 %, alanine transaminase in 52.1 %, and total bilirubin in 64.1 %. Lack of baseline labs was more pronounced in patients initiated on a DOAC in the outpatient setting. Dosing and baseline lab collection for DOAC initiation were suboptimal in all settings analyzed. Targeted interventions are needed to ensure the safe and appropriate use of DOAC therapy.

Entities:  

Keywords:  Direct oral anticoagulants; Initiation; New oral anticoagulants; Prescribing; Risk factors; Target specific oral anticoagulants

Mesh:

Substances:

Year:  2017        PMID: 27757787     DOI: 10.1007/s11239-016-1435-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  19 in total

1.  Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Elie A Akl; Mark Crowther; David D Gutterman; Holger J Schuünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Site-level variation in and practices associated with dabigatran adherence.

Authors:  Supriya Shore; P Michael Ho; Anne Lambert-Kerzner; Thomas J Glorioso; Evan P Carey; Fran Cunningham; Lisa Longo; Cynthia Jackevicius; Adam Rose; Mintu P Turakhia
Journal:  JAMA       Date:  2015-04-14       Impact factor: 56.272

Review 3.  Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review.

Authors:  Amit X Garg; Neill K J Adhikari; Heather McDonald; M Patricia Rosas-Arellano; P J Devereaux; Joseph Beyene; Justina Sam; R Brian Haynes
Journal:  JAMA       Date:  2005-03-09       Impact factor: 56.272

4.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

5.  Oral apixaban for the treatment of acute venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Urszula Masiukiewicz; Raphael Pak; John Thompson; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2013-07-01       Impact factor: 91.245

6.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

7.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 8.  Effect of clinical decision-support systems: a systematic review.

Authors:  Tiffani J Bright; Anthony Wong; Ravi Dhurjati; Erin Bristow; Lori Bastian; Remy R Coeytaux; Gregory Samsa; Vic Hasselblad; John W Williams; Michael D Musty; Liz Wing; Amy S Kendrick; Gillian D Sanders; David Lobach
Journal:  Ann Intern Med       Date:  2012-07-03       Impact factor: 25.391

9.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

10.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

View more
  17 in total

1.  Burden of Inappropriate Prescription of Direct Oral Anticoagulants at Hospital Admission and Discharge in the Elderly: A Prospective Observational Multicenter Study.

Authors:  Antoine Bruneau; Camille Schwab; Maud Anfosso; Christine Fernandez; Patrick Hindlet
Journal:  Drugs Aging       Date:  2019-11       Impact factor: 3.923

2.  Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.

Authors:  Maria Cristina Vedovati; Maria Giulia Mosconi; Federico Isidori; Giancarlo Agnelli; Cecilia Becattini
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

3.  Quality of clinical direct oral anticoagulant prescribing and identification of risk factors for inappropriate prescriptions.

Authors:  Zhu Xian Zhang; Ewoudt M W van de Garde; Maaike Söhne; Ankie M Harmsze; Marcel P H van den Broek
Journal:  Br J Clin Pharmacol       Date:  2020-03-13       Impact factor: 4.335

4.  Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients.

Authors:  Bruria Hirsh Raccah; Amihai Rottenstreich; Netanel Zacks; Ilan Matok; Haim D Danenberg; Arthur Pollak; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2019-05       Impact factor: 2.300

5.  Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation.

Authors:  Carlotta Franchi; Stefania Antoniazzi; Marco Proietti; Alessandro Nobili; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2018-06-19       Impact factor: 4.335

6.  Rationale and design of a prospective, multicenter, cross-sectional study of appropriateness evaluation of the prescription of non-vitamin K antagonist oral anticoagulants for Chinese atrial fibrillation patients (Chi-NOACs-AF trial).

Authors:  Zheng Ding; Chi Zhang; Yi-Yi Qian; Na Wang; Zhi-Chun Gu; Hang Xu; Ying-Li Zheng
Journal:  Ann Transl Med       Date:  2021-04

7.  Appropriateness of DOAC Prescribing Before and During Hospital Admission and Analysis of Determinants for Inappropriate Prescribing.

Authors:  Souad Moudallel; Stephane Steurbaut; Pieter Cornu; Alain Dupont
Journal:  Front Pharmacol       Date:  2018-10-30       Impact factor: 5.810

8.  Patient Education on Oral Anticoagulation.

Authors:  Emily M Hawes
Journal:  Pharmacy (Basel)       Date:  2018-04-20

9.  Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation.

Authors:  Alan Sugrue; David Sanborn; Mustapha Amin; Medhat Farwati; Haarini Sridhar; Azza Ahmed; Ramila Mehta; Konstantinos C Siontis; Siva K Mulpuru; Abhishek J Deshmukh; Bernard J Gersh; Samuel J Asirvatham; Malini Madhavan
Journal:  Am J Cardiol       Date:  2020-12-29       Impact factor: 2.778

10.  The role of clinical pharmacy anticoagulation services in direct oral anticoagulant monitoring.

Authors:  Aubrey E Jones; Jordan B King; Kibum Kim; Daniel M Witt
Journal:  J Thromb Thrombolysis       Date:  2020-10       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.